Neo stem RedChip's Global Online CEO Conference

INVESTOR
PRESENTATION
NASDAQ: NBS
JULY 2014
TRANSFORMING MEDICINE

NASDAQ:NBS | www.neostem.com > 1
FORWARD-LOOKING STATEMENTS
This presentation contains “forward-looking” statements within the meaning of the Private Securities Litigation Reform Act of 1995, as well as historical information. Such
forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements, or industry
results, to be materially different from anticipated results, performance or achievements expressed or implied by such forward-looking statements. When used in this
presentation, statements that are not statements of current or historical fact may be deemed to be forward-looking statements. Without limiting the foregoing, the words
“plan,” “intend,” “may,” “will,” “expect,” “believe,” “could,” “anticipate,” “estimate,” or “continue” or similar expressions or other variations or comparable terminology are
intended to identify such forward-looking statements, although some forward-looking statements are expressed differently. We remind readers that forward-looking
statements are merely predictions and therefore inherently subject to uncertainties and other factors and involve known and unknown risks that could cause the actual results,
performance, levels of activity or our achievements or industry results, to be materially different from any future results, performance levels of activity or our achievements or
industry results expressed or implied by such forward-looking statements. Such forward looking statements appear in this presentation. Factors that could cause our actual
results to differ materially from anticipated results expressed or implied by forward-looking statements include, among others:
• our ability to obtain sufficient capital or strategic business arrangements to fund our operations and expansion plans, including meeting our financial obligations under
various licensing and other strategic arrangements, the funding of our clinical trials for product candidates in our development programs for our Targeted Immunotherapy
Program, our CD34 Cell Program and our T Regulatory Cell Program, and the commercialization of the relevant technology;
• our ability to build and maintain the management and human resources infrastructure necessary to support the growth of our business;
• our ability to integrate our acquired businesses successfully and grow such acquired businesses as anticipated, including expanding our PCT business internationally;
• whether a large global market is established for our cellular-based products and services and our ability to capture a meaningful share of this market;
• scientific and medical developments beyond our control;
• our ability to obtain and maintain, as applicable, appropriate governmental licenses, accreditations or certifications or comply with healthcare laws and regulations or any
other adverse effect or limitations caused by government regulation of our business;
• whether any of our current or future patent applications result in issued patents, the scope of those patents and our ability to obtain and maintain other rights to
technology required or desirable for the conduct of our business; our ability to commercialize products without infringing the claims of third party patents;
• whether any potential strategic benefits of various licensing transactions will be realized and whether any potential benefits from the acquisition of these licensed
technologies will be realized;
• the results of our development activities, including the results of our planned Melapuldencel-T Phase 3 clinical trial, our PreSERVE Phase 2 clinical trial of AMR-001 and
planned clinical trials;
• our ability to complete our other planned clinical trials (or initiate other trials) in accordance with our estimated timelines due to delays associated with enrolling patients
due to the novelty of the treatment, the size of the patient population and the need of patients to meet the inclusion criteria of the trial or otherwise;
• the other factors discussed in “Risk Factors” in our Form 10-K filed with the Securities and Exchange Commission (“the SEC”) on March 13, 2014, and elsewhere in the
Annual Report on Form 10-K; and
• the Company’s acquisition of California Stem Cell, Inc. (“CSC Acquisition”) and the ongoing operations of our NeoStem Oncology, LLC will subject the Company to additional
risks. Our Current Report on Form 8-K filed on May 8, 2014 reporting the closing of the CSC Acquisition contains a discussion of the risk factors related to the CSC
Acquisition and our NeoStem Oncology, LLC subsidiary.
The factors discussed herein, including those risks described in Item 1A. “Risk Factors” in the Company's Annual Report on Form 10-K filed with the SEC on March 13, 2014,
the "Risk Factors" described in the Current Report on Form 8-K filed by the Company on May 8, 2014 and in the Company's other periodic filings with the Securities and
Exchange Commission (the “SEC”) which are available for review at www.sec.gov under “Search for Company Filings” could cause actual results and developments to be
materially different from those expressed or implied by such statements. All forward-looking statements attributable to us are expressly qualified in their entirety by these and
other factors. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Except as required by law, the
Company undertakes no obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise.

CELL THERAPY
Using cells to prevent or treat disease and modulate the immune system
Holds the promise to dramatically transform the course of medicine
Improve clinical outcomes Reduce overall healthcare costs

ABOUT NEOSTEM
Leader in the emerging cellular therapy industry developing novel
proprietary cell therapy products as well as generating revenue
through a contract development and manufacturing organization that
we believe will benefit from the growth of this industry
■ Integrated entity with platform technologies, a strong pipeline, and a
revenue-generating contract development and manufacturing service
business
■ Recently expanded pipeline into cancer immunotherapies through
acquisition of California Stem Cell, Inc. with Phase 3 candidate
■ Over $41M in cash as of March 31, 2014
■ Headquarters in New York City
■ GMP-compliant facilities in Allendale, NJ; Mountain View, CA; and
Irvine, CA
■ 151 employees as of May 8, 2014

NEOSTEM HAS AN
INTEGRATED BUSINESS MODEL
Therapeutic development around a significant IP portfolio and a
revenue-generating service business allows for cost effective in-
house product development and immediate revenue

DEVELOPMENT HIGHLIGHTS:
MULTIPLE PLATFORM TECHNOLOGIES
DEVELOPING A PORTFOLIO OF CELL THERAPY
PRODUCTS THAT LEVERAGES THE BODY’S NATURAL
ABILITY TO HEAL AND FIGHT DISEASE
 CANCER TREATMENT – TARGETED IMMUNOTHERAPY PROGRAM
 ISCHEMIC REPAIR – CD34 CELL PROGRAM
 IMMUNE MODULATION – T REGULATORY CELL PROGRAM
 TISSUE REGENERATION – VSEL™ TECHNOLOGY AND
DERMATOLOGY PROGRAM

TARGETED IMMUNOTHERAPY PROGRAM
RATIONALE
 Cancer initiating (stem) cells isolated from patient tumor provide potent signature
antigens to educate and direct the immune system
 Immunotherapy product uniquely targets the patient’s cancer initiating (stem) cells,
which are otherwise capable of reconstituting the tumor
 Therapies that fail to target cancer initiating (stem) cells are not likely to prevent
recurrence of tumors
Cancer initiating (stem) cells* can move through the blood stream to form new metastasis and
grow to form new tumors
* These cells are defined as invasive migratory cancer initiating cells capable of reconstituting and developing new tumors

TARGETED IMMUNOTHERAPY
TREATMENT PROCESS
STEP 1:
Creation of the
treatment begins
with the surgical
resection of the
patient’s tumor
STEP 2:
(DAY 0 - WEEK 6)
The cancer initiating
(stem) cells from the
tumor are isolated,
expanded, and
irradiated to render
them inactive
STEP 3:
(PRIOR TO WEEK 6)
Patient undergoes
leukapheresis, a
standard procedure
in which monocytes
are extracted from
circulating blood
STEP 4: (WEEK 6)
Monocytes mature
into dendritic cells,
and are exposed to
the irradiated cancer
initiating (stem) cells,
learning how to
identify cancer
initiating (stem) cells
based on their
antigen signature
STEP 5:
(WEEK 6 - WEEK 8)
Mature, reactive
dendritic cells are
cryopreserved,
quality controlled,
then shipped to the
clinical site
STEP 6:
When convenient for the
clinician, treatment
begins (includes eight
injections administered
over the course of six
months)

FEATURES OF OUR TARGETED
IMMUNOTHERAPY PROGRAM
OUR IMMUNOTHERAPY OVERCOMES
Presents the entire spectrum of patient-specific
cancer initiating (stem) cells for the immune
system to target
Limited antigen targeting
Targets the cancer initiating (stem) cells that
express antigens associated with mutated cell
lineages
Tumor mutation/escape
Induces or enhances persistent T-cell immunity
with activated dendritic cells
Weak immune response
Uses autologous cancer antigen immune priming Toxicity

FIRST TARGET INDICATION: MELANOMA
BASICS OF MELANOMA
 Most lethal form of skin cancer
 Most often caused by unrepaired DNA damage to skin
cells from UV radiation
 120,000 new cases per year in U.S.1
 Kills an estimated 8,790 in U.S. annually2
SURVIVAL RATE
 Stage IV metastatic melanoma – 15% five-year survival
rate with current therapies3
CURRENT MAJOR-MARKET* LANDSCAPE FOR
MALIGNANT MELANOMA
 111,520 newly diagnosed patients
 2012 Total: $950 million
 76% of cost is spent on immunotherapies
1. American Cancer Society
2. Skin Cancer Foundation
3. AJCC Cancer Staging 2010 (based on 17 academic centers)
All other data from Decision Resources Malignant Melanoma – 2013 Report
* U.S., Europe and Japan
Brain
Lung
Bone
Liver
Distant
Metastases
Hypodermis
Epidermis
Dermis
{
{
{
Skin Tumors

OTHER THERAPEUTICS
FOR MELANOMA
THERAPY 2 YR OVERALL
SURVIVAL
SIDE EFFECTS ESTIMATED
COST
Proleukin
(Interleukin-2)
Prometheus Labs
25%1 Capillary Leak Syndrome
Impaired Neutrophil Function
Disseminated Infection
Sepsis
>$100,000
Yervoy (Ipilimumab)
(CTLA-4 inhibitor)
Bristol Myers –
Squibb
28%2 Enterocolitis
Hepatitis
Dermatitis
Neuropathy
Endocrinopathy
GI Disorders
>$100,000
Oral BRAF inhibitors
& MEK inhibitors
28%3 Cutaneous Malignancies
Hypersensitivity Reactions
Tumor Promotion in BRAF wild-type
QT Prolongation
Hepatotoxicity
>$100,000
Chemotherapy 15%4 Anemia
Fatigue
Risk of Infection
Nausea/Diarrhea/Constipation
~$50,000
1. Eton JCO 2002, Atkins JCO 2008
2. Hodi NEJM 2010, Robert NEJM 2010, Wolchok Ann Oncol 2013
3. Estimated
4. Chapman JCO 1999, Middleton JCO 2000, Ranson JCO 2007, Robert NEJM 2011, Chapman NEJM 2011 (Derived from a range of 9 – 20%)

PHASE 2 RESULTS FOR
MELAPULDENCEL-T
Dillman, et al. Journal Immunotherapy 2012
31%
0%
20%
40%
60%
80%
Control Group
(Irradiated Tumor Cells Only)
Melapuldencel-T
Treatment Group
2 YEAR OVERALL SURVIVAL
72%
• No serious adverse events related to immunotherapy
• Minor local injection site reactions

INTUS PHASE 3 SPECIAL PROTOCOL
ASSESSMENT (SPA) STUDY DESIGN
STUDY NAME
TARGET Patients with Stage IV or recurrent Stage III metastatic
melanoma
LOCATION AND NUMBER
OF SUBJECTS
Potentially United States and Europe, multicenter, 250 patients*
DESIGN Double blind, placebo controlled, randomized (2:1)
ENDPOINT Overall survival
TREATMENT GROUP Melapuldencel-T (autologous dendritic cells pulsed with
irradiated tumor cells in GM-CSF)
CONTROL GROUP Autologous mononuclear cells (MC) in GM-CSF
SPECIAL PROTOCOL
ASSESSMENT (SPA)
Indicates FDA is in agreement with the design, clinical endpoints
and planned clinical analysis of this Phase 3 trial and could serve
as the basis for a Biologics License Application
* Company may overenroll by 10%

CD34 CELL PROGRAM:
ENHANCING THE BODY’S
NATURAL REPAIR MECHANISM
■ Following a heart attack,
apoptosis and progressive
cardiomyocyte loss leads to
infarct expansion
■ ST segment Elevation MI (STEMI)
patients are at a high risk of a
progressive deterioration in heart
muscle function that leads to
worsening of heart function,
morbidity and mortality
■ CD34/CXCR4 cells are a natural
repair mechanism
■ This mechanism works the same
for other areas of vascular
insufficiency such as chronic
heart failure
THE NATURAL PROGRESSION OF DISEASE POST-STEMI
AMR-001 BRINGS REPAIR SYSTEM TO THE HEART TO
PRESERVE FUNCTION AFTER A STEMI

PRESERVE PHASE 2 STUDY
TREATMENT PROCESS
DAY 1:
Patient comes to
emergency room with
heart attack and receives
stent
DAY 4:
Cardiac magnetic
resonance to
assess ventricular
function
DAY 4-9:
Mini bone marrow
procedure to
harvest cells
DAY 5-9:
6-8 hour cell
separation
process to
isolate
CD34/CXCR4
cells
DAY 6-11:
Injection of cell therapy
into the infarct-related
artery

FEATURES AND BENEFITS OF
AMR-001
■ CD34/CXCR4 cells home to the viable
tissue surrounding the infarcted (dead)
myocardium (peri-infarct zone) after
administration and persist
■ Autologous cells take up residence in the
peri-infarct zone, likely promoting
angiogenesis (development and formation
of new blood vessels)
■ Cell preparation has a 72 hour shelf life
and is infused into patient 5 to 11 days
following an acute myocardial infarction
(AMI)
► After the pro-inflammatory “hot phase”
► Prior to permanent scar formation
■ Amplifies the body’s natural repair
mechanism
■ Cells are not expanded – no risk of genetic
mutation
■ Cells are autologous – no immunogenicity
risk
■ Delivery where cells are needed without
having to inject into myocardium
► Safer and greater distribution
FEATURES BENEFITS

PHASE 1 RESULTS POINT TO
AMR-001 POTENTIAL
Patients dosed ≥ the threshold dose of 10
million cells showed significant improvement
in perfusion
Increasing doses of CD34/SDF-1 mobile cells
reduced the size of the infarct region as
measured by CMR
DSMB DETERMINED THAT THERE
WERE NO SAFETY CONCERNS THAT
WARRANTED ANY ACTION
Quyyumi AmHtJ 2011 and data on file
Y = Δ Infarct % LV Mass
X = Dose of SDF-1 mobile CD34 cells
R2 = 0.4971
P = .015
At threshold dose of 10 million cells or more,
no individuals showed decrease in LVEF
RTSS (HYPOPERFUSION)
COHORT BASE LINE 6 MONTHS DELTA % CHANGE
Control 259.0 273.5 +14.5 +5.6
5M Cells 714.2 722.0 +7.8 +1.1
10M Cells 998.6 635.8 -362.8 -36.4
15M Cells 584.0 462.0 -122.0 -20.9 % of
individuals
with decrease
in left
ventricular
ejection
fraction (LVEF)
CD34 cells (millions)
No individuals
showed a decrease
in LVEF
Threshold
DOSE RESPONSE CORRELATED
WITH MOBILE CD34 CELLS

MIGRATORY CAPACITY OF ADMINISTERED
CD34 CELLS ASSOCIATED WITH EVENT-
FREE SURVIVAL POST AMI
Assmus, B., et al. (2014) Long-term clinical outcome after intracoronary application of bone marrow-derived mononuclear cells for acute
myocardial infarction: migratory capacity of administered cells determines event-free survival. European Heart Journal
 Recently published study demonstrated administration of autologous SDF-1 migratory
CD34 cells, significantly reduces cumulative incidence of major adverse clinical cardiac
events following acute myocardial infarction (AMI)
Event-free survival (%)
(cardiac, cardiovascular and unknown death, rehospitalization for heart failure)

PRESERVE PHASE 2 STUDY:
ENROLLMENT COMPLETED WITH
ANTICIPATED DATA RELEASE 2H 2014
TARGET Post-AMI patients
KEY INCLUSION CRITERIA Confirmation of ST Elevation MI (STEMI); ejection fraction
< 48% at day 4; state of the art care post stenting
LOCATION AND NUMBER
OF SUBJECTS
United States, 60 centers, 160 patients (enrollment
completed)
DESIGN Double blind, placebo controlled, randomized (1:1)
PRIMARY ENDPOINT Change in cardiac perfusion (RTSS by SPECT) from
baseline to 6 months
OTHER ENDPOINTS Secondary endpoints to determine preservation of cardiac
function and clinical events:
■ CMR to measure LVEF, LVESV, LVEDV, regional
myocardial strain, infarct/peri-infarct regional wall
motion abnormalities, and infarct size (baseline and 6
months)
■ Quality of Life measures: (KCCQ & SAQ)
■ Reduction in cumulative MACE and other adverse
clinical cardiac events at 6, 12, 18, 24, and 36 months
TREATMENT Single dose via infarct related artery with minimum dose
for release >10MM CD34+ cells

T REGULATORY CELL PROGRAM:
POTENTIAL TO LIMIT AUTOIMMUNITY
TREG THERAPY REPRESENTS A NOVEL APPROACH FOR RESTORING IMMUNE BALANCE
BY ENHANCING T REGULATORY CELL NUMBER AND FUNCTION1
1. Chai, Jian-Guo et al, Journal of Immunology 2008; 180;858-869

FEATURES OF OUR TREG PROGRAM
FEATURES OF TREGS:
■ Natural part of immune system
■ Regulate activity of T effector cells (responsible for protection
from viruses and foreign antigens)
■ In autoimmune disease it is thought that deficient Treg activity
permits the T effector cells to attack the body’s own tissues
SIGNIFICANT COLLABORATIONS:
■ Partnership with Becton Dickinson (11.5% program ownership)
■ Accelerated development through collaboration with University of
California, San Francisco and laboratory of Dr. Jeffrey Bluestone

DIABETES MELLITUS TYPE-1 (T1D)
 Diabetes is leading cause of kidney
failure, new cases of adult blindness,
and non-traumatic lower-limb
amputations
 Results in total insulin deficiency
 At time of diagnosis, there are still
insulin-secreting beta cells in islets
 Also called insulin dependent
diabetes or juvenile diabetes
 Affects >34 million worldwide, 1 in
300 children and more adults
 Autoimmune destruction of insulin-
producing (beta cells) of the
pancreas
Islet at diagnosis of T1D
Insulin-secreting cells
Glucagon-secreting cells
Healthy islet
Insulin-secreting cells
Glucagon-secreting cells

ECONOMIC IMPACT OF T1D
THE ECONOMIC BURDEN OF T1D IN THE U.S. IS ESTIMATED AT $14.9 BILLION1
 Average economic burden per person with diabetes is larger for T1D vs T2D
PREVENTION IS KEY - MEDICAL COSTS ASSOCIATED WITH T1D INCREASE
SUBSTANTIALLY WITH AGE AND DURATION OF DISEASE
 Annual medical costs per person increase with age at a much faster rate for those with T1D vs
T2D
 For T1D the average medical cost per case increases from ~$4,000 for people younger than age
44 to ~$35,000 for the population age 65 and older
 Increased utilization of institutional care in elderly T1D patients
1. Dall TM et al. Population Health Management 2009;12:103–110
$2 BILLION ESTIMATED MARKET SIZE FOR INSULIN SALES IN 2017
 For the T1D indication alone
UNMET NEED FOR ß-CELL PRESERVING/PREVENTATIVE TREATMENTS FOR T1D

TREG IMMUNOTHERAPY WORKS IN
MODEL OF T1D
Tregs effectively suppress diabetes
0
10
20
30
40
50
60
70
0 5 10 15 20
Weeks after treatment
Remission(%)
untreated
Ag-specific Treg therapy
Ag-specific Tregs reverse diabetes
Tang, Bluestone, et al.

T1D TREG TREATMENT PROCESS
DAY 1:
Screening and
enrollment
DAY 5-7:
Blood draw from
patient
DAY 7-21:
Manufacturing
including expansion
DAY 21:
Infusion of Treg therapy
to patient

ADMINISTRATION OF CD4+CD25highCD127-
REGULATORY T CELLS PRESERVES
BETA CELL FUNCTION IN T1D IN CHILDREN*
Not Treated
Time 0
Not Treated
4 mo
0 2 wk 2 mo 4 mo
 First human evidence of therapeutic
effect of autologous Treg therapy
protection of pancreatic function in new
onset T1D in children
 C-peptide levels stabilized
 Reduction of insulin requirements
 20% of patients able to come off of
exogenous insulin four months after
treatment
 One year follow-up: evidence that Treg
therapy preserves function of pancreatic
islets cells
* Children aged 8-16 in studyMarek-Trzonkowska N et al. Diabetes Care 2012;35:1817-1820
Marek-Trzonkowska N et al. Clinical Immunology 2014
Treated

MARKET OPPORTUNITY IN ASTHMA
ASTHMA
■ Affects 25 million in U.S. and 300 million worldwide
■ Asthma accounts for $56 billion in annual direct and
indirect health care costs in U.S.
■ Steroid resistant asthma afflicts less than 5% of the total
asthma population, but accounts for up to 50% of
healthcare spending on asthma
■ Initiating proof-of-concept study planned to initiate in
2014

TISSUE REGENERATION PROGRAMS
VSEL™ TECHNOLOGY: POTENTIAL TO REPAIR
DAMAGED TISSUE
■ Evaluating therapeutic potential of very small embryonic-
like stem cells (VSELs™)
■ Research suggests multipotency and multi-lineage
differentiation into all basic cell types (mesoderm,
ectoderm, endoderm)
■ Exploring the development for retinal repair and the
treatment of chronic wounds
■ $4.5 million of grants toward preclinical VSEL™ research
DERMATOLOGY PROGRAM: TOPICAL PRODUCT
BASED ON STEM CELL DERIVED GROWTH FACTORS
■ Exploring potential for fine lines and wrinkles, psoriasis,
and wound care
BONE
mesoderm
NEURON
ectoderm
PANCREAS
endoderm
VSELs™

INTELLECTUAL PROPERTY
TARGETED IMMUNOTHERAPY PROGRAM (CANCER TREATMENT)
■ 28 pending patents in the U.S. and OUS with coverage including:
► Antigen-presenting cancer vaccines; Individualized high purity carcinoma initiating (stem)
cells for target indications, methods and use of same; and rapid methods to produce high
purity cancer initiating (stem) cells
CD34 CELL PROGRAM (ISCHEMIC REPAIR)
■ Broad and growing patent portfolio supports cardiac conditions and a broad range of other
conditions caused by underlying ischemia
■ 16 granted or allowed composition of matter and methods patents
■ Patent Applications: 20 U.S. and OUS patents pending
T REGULATORY CELL PROGRAM (IMMUNE MODULATION)
■ Exclusive rights to 23 issued patents covering isolation, activation, expansion and methods of
treating or preventing certain conditions and/or diseases using Tregs in U.S. and major
international markets
■ Includes composition of matter patents and method patents
VSEL™ TECHNOLOGY (TISSUE REGENERATION)
■ In-licensed from the University of Louisville the world-wide patent rights and know-how
regarding the isolation, purification and therapeutic use of very small embryonic-like
(VSEL™) stem cells

2014 OUTLOOK:
CLINICAL MILESTONES
1. The last patient primary endpoint follow-up for this study occurred in June followed by data lock and analysis with data available in 2H 2014.

MOUNTAIN VIEW, CALIFORNIA (25,000 ft2)
ISO Class 7 / Class 10,000 suites
Recent expansion of clean room space
ALLENDALE, NEW JERSEY (30,000 ft2)
ISO Class 6 / Class 1,000 suite
Recent expansion of clean room space
PCT PROVIDES OUTSOURCED
MANUFACTURING CAPABILITIES TO
CELL THERAPY INDUSTRY
■ High quality manufacturing capabilities with 15-year
track record of success
■ Proven efficiencies and reduced capital investment
for customers through outsourcing
■ Demonstrated regulatory expertise:
► 50+ EU and U.S. regulatory filings;
► All clinical trial phases including BLA submission
and product approval by FDA
■ Significant focus on innovation, engineering and
automation
■ EU product distribution requirement compliant
■ Continuing to expand commercial capabilities in the
U.S. and internationally
IRVINE, CALIFORNIA (12,500 ft2)

CONTRACT MANUFACTURING IS A
SIGNIFICANT OPPORTUNITY
EXAMPLES OF CONTRACT SERVICES POTENTIAL FROM CONCEPTION TO COMMERCIALIZATION*
*Based on industry experience and estimated potential future commercial manufacturing in the industry
LOW COMPLEXITY PRODUCT MEDIUM COMPLEXITY PRODUCT HIGH COMPLEXITY PRODUCT
PRECLINICAL DRUG
DISCOVERY CONTRACT
12 to 18 Month Engagement 12 to 24 Month Engagement 24 to 36 Month Engagement
$50,000 to $250,000 $250,000 to $500,000 $500,000 to $1,000,000
PHASE 1 CLINICAL TRIAL
MANUFACTURING CONTRACT
6 to 12 Month Eng. 12 to 18 Month Eng. 12 to 24 Month Eng.
5 to 25 Units Produced 25 to 50 Units Produced 50 to 100 Units Produced
$250,000 to $750,000 $625,000 to $1,250,000 $1,000,000 to $2,000,000
25 to 50 Units Produced 100 to 200 Units Produced 200 to 400 Units Produced
$625,000 to $1,250,000 $2,000,000 to $4,000,000 $3,000,000 to $6,000,000
50 to 100 Units Produced 200 to 400 Units Produced 400 to 1,000 Units Produced
$1,000,000 to $2,000,000 $3,000,000 to $6,000,000 $4,000,000 to $10,000,000
COMMERCIAL
Est. Peak Annual Sales Est. Peak Annual Sales Est. Peak Annual Sales
2,500 to 5,000 Units 10,000 to 25,000 Units 25,000 to 50,000 Units
$38M to $75M / Yr. $80M to $200M / Yr. $125 to $250M / Yr.

Robert Dickey IV, MBA – Chief Financial Officer
 15+ years management experience at life science companies,
including cell therapy experience as CFO of StemCyte,
following a career as an investment banker at Lehman
Brothers
Andrew L. Pecora, MD – Chief Visionary Officer
 Chief Innovations Officer at John Theurer Cancer Center at
Hackensack University Medical Center; Co-founder of PCT;
Significant experience in design and conduct of clinical trials
Douglas W. Losordo, MD – Chief Medical Officer
 Leader in cell therapy research and renowned cardiologist;
Obtained over $35 million in NIH funding during career-long
efforts to develop novel therapeutics
Robert A. Preti, PhD – Chief Scientific Officer, President of PCT
 Leading authority on cell engineering; Co-founder of PCT; 10
years prior experience as Director of Hematopoietic Stem Cell
Processing & Research Laboratory
Stephen W. Potter, MBA – Executive Vice President
 Biotech and pharma experience: Osiris Therapeutics (approval of
Prochymal®, first-ever stem cell drug therapy), Genzyme, DuPont
Pharmaceuticals, Booz Allen & Hamilton
Robin Smith, MD, MBA – Chief Executive Officer
 Leading NeoStem since 2006, completed six acquisitions and
one divestiture; Raised over $180 million; Extensive
experience in executive and board level capacities for
medical enterprises and healthcare-based entities
MANAGEMENT HIGHLIGHTS
David Altarac, MD, MPA – VP, Regulatory Affairs
 Extensive experience in U.S. and global regulatory affairs,
including strategy, operations, labeling and departmental
leadership; 13 year tenure at Merck
Jonathan Sackner-Bernstein, MD – VP, Clinical Development &
New Technologies
 Formerly FDA Assoc. Center Director for Innovation and
Technology; At FDA launched innovation initiative; Established
inter-agency relationship between FDA and DARPA
Adel Nada, MD – VP, Immunotherapy
 Formerly Senior Medical Director, Cardiovascular Cell Therapies at
Baxter Healthcare; Led Clinical Pharmacology Medical Dept. at
Abbott Laboratories
Hans Keirstead, PhD – President, NeoStem Oncology
 15+ years of experience; CEO of California Stem Cell prior to
acquisition; Founder of Stem Cell Research Center, University
of California at Irvine; Previously Professor, UCI; Previously
CEO of Ability Biomedical
Robert Dillman, MD – VP, Oncology, NeoStem Oncology
 CMO of California Stem Cell prior to acquisition; Executive Medical
Director of the Hoag Hospital Institute for Research and
Education and Clinical Professor of Medicine at UC Irvine
Catherine M. Vaczy, Esq. – General Counsel
 Senior business executive and counsel with 20+ years of
leadership experience in the biotech industry; Former senior
executive at ImClone Systems ($1 billion co-development deal in
oncology forged with Bristol-Myers Squibb)

Robin Smith, MD, MBA
Chairman of the Board
 MD – Yale; MBA – The Wharton School
 Formerly President & CEO IP2M, EVP & CMO HealthHelp
 Experience - Trustee of NYU Medical Center; Chairman of the Board of NYU Hospital for Joint Diseases
(through November 2009) and Chairman of Stem for Life Foundation
Richard Berman
Independent Director
 BS and MBA – NYU; JD – Boston College
 Over 35 years of venture capital, management, M&A experience
 Experience – Current Board of Directors of Apricus Biosciences, Easylink Services International, Inc.,
Advaxis, Inc., Broadcaster, Inc., National Investment Managers
Drew Bernstein, CPA
 BS – University of Maryland Business School
 Licensed in State of New York; member AICPA, NYSSCPA and NSA
 Experience – Bernstein & Pinchuk LLP (member of BDO Seidman Alliance); PRC auditing; 200+ real
estate transactions with $3B+ aggregate value; accountant and business advisor
Martyn Greenacre, MBA
 BA – Harvard College; MBA – Harvard Business School
 Experience – Board and executive positions for multiple biopharmaceutical companies; Former CEO of
Delsys Pharmaceutical Corporation and Zynaxis Inc; Chairman of the Board of BMP Sunstone Corporation
Steven M. Klosk
 BS Industrial & Labor Relations – Cornell; JD – New York Law School
 Experience – President, CEO & Director of Cambrex Corporation (leading provider of active
pharmaceutical ingredients) since 2008 driving significant revenue growth during his tenure
Steven Myers
Independent Lead Director
 BS Mathematics – Stanford University
 Experience – Founder/Chairman/CEO SM&A (competition management services); career in aerospace and
defense sectors supporting DoD & NASA programs
Andrew Pecora, MD, FACP
Director
 MD — University of Medicine and Dentistry of New Jersey
 Experience – Chief Innovations Officer, Professor and Vice President of Cancer Services at John Theurer
Cancer Center at Hackensack University Medical Center, and Managing Partner of the Northern New
Jersey Cancer Center
Eric Wei
Director
 BS – Mathematics & Economics – Amherst College; MBA – The Wharton School
 Experience – Founder/Managing Partner of RimAsia Capital partners (private equity); Formerly with
Peregrine Capital, Prudential Securities, Lazard Freres, Citibank, Gilbert Global Equity Partners, and
Crimson Asia Capital Partners
BOARD OF DIRECTORS

KEY METRICS
MARKET METRICS
MARKET CAPITALIZATION1 $203M
STOCK PRICE2 $5.98
52 WEEK RANGE2 $5.00 - $9.89
FLOAT1 29.8M
INSIDER HOLDINGS1 11.9%
FINANCIAL METRICS
REVENUE3 $4.1M (First Quarter)
CASH4 $41.4M
COMMON SHARES
OUTSTANDING1
33.9M
WARRANTS1 4.0M
(avg. warrant exercise price of $14.22)
OPTIONS1 4.3M
(avg. option exercise price of $9.77)
1. As of May 8, 2014 (Market capitalization based on a $5.98 share price)
2. As of May 6, 2014
3. For the three months ended March 31, 2014
4. As of March 31, 2014

UNIQUE BUSINESS MODEL
COMBINATION OF A LATE STAGE CLINICAL PIPELINE AND
A REVENUE-GENERATING SERVICE BUSINESS
CANCER TREATMENT – TARGETED IMMUNOTHERAPY PROGRAM
■ Stage IV and recurrent Stage III melanoma – Intus Phase 3 study approved, initiating 2H 2014
ISCHEMIC REPAIR – CD34 CELL PROGRAM
■ Acute myocardial infarction – PreSERVE Phase 2 study (data available 2H 2014)
IMMUNE MODULATION – T REGULATORY CELL PROGRAM
■ Type 1 diabetes – Preparing for Phase 2 study, Phase 1 data readout presented at ADA June 2014
■ Steroid resistant asthma – Preparing for Phase 1 study in Canada
TISSUE REGENERATION
■ VSEL™ Technology - Macular degeneration, wound healing, bone regeneration – preclinical
■ Human stem cell derived growth factors for dermatologic applications – Skin health, psoriasis, wound care
CELL THERAPY MANUFACTURING – PROGENITOR CELL THERAPY
■ Cost effective in-house product development and immediate revenue and cash flow generation
■ Manufacturing, regulatory, and commercialization expertise for therapeutics development
■ Cell therapy automation to lower cost and improve efficiency
■ Manufacturing expansion in U.S. and internationally

CONTACT INFORMATION
NEOSTEM, INC.
NASDAQ: NBS
WWW.NEOSTEM.COM
ROBIN SMITH, MD, MBA
CHAIRMAN & CEO
PHONE: (212) 584-4174
EMAIL: RSMITH@NEOSTEM.COM

APPENDIX

SINCE 2006, ACCESSED OVER $189M
AND COMPLETED MULTIPLE M&A
TRANSACTIONS AND ONE DIVESTITURE

AMORCYTE
SCIENTIFIC ADVISORY BOARD
Andrew L. Pecora, MD, FACP, CPE
SAB Administrative Chairman
Hackensack University Medical Center
Chief Scientific Officer, Amorcyte
Eugene Braunwald, MD, FRCP Brigham & Women’s Hospital
Bernard J. Gersh, MD, ChB, DPhil, FRCP The Mayo Clinic
Dean J. Kereiakes, MD, FACC The Christ Hospital Heart of Greater Cincinnati
Douglas L. Mann, MD, FACC Washington University School of Medicine
Emerson C. Perin, MD, PhD, FACC Texas Heart Institute
Bertram Pitt, MD University of Michigan School of Medicine
Arshed Quyyumi, MD, FRCP, FACC, Emory University School of Medicine
Edmund K. Waller, MD, PhD, FACP Emory University School of Medicine
James T. Willerson, MD Texas Heart Institute
Joseph Wu, MD, PhD Stanford University School of Medicine

ATHELOS
SCIENTIFIC ADVISORY BOARD
Robert A. Preti, PhD
SAB Administrative Chairman
Chief Scientific Officer of NeoStem and PCT, President of PCT
Jeffrey Bluestone, PhD University of California, San Francisco, Diabetes Center
David A. Horwitz, MD University of Southern California
Robert Korngold, PhD Hackensack University Medical Center
Robert S. Negrin, MD Stanford University
David Peritt, PhD Hospira
Noel L. Warner, PhD BD Biosciences

VSEL™ TECHNOLOGY
ACADEMIC COLLABORATORS
Mariusz Ratajczak, MD, PhD, Dsci University of Louisville
Russell Taichman, DMD, DMSc University of Michigan
Vincent Falanga, MD Boston University
Michael Young, PhD Schepens Eye Research Institute, Harvard Medical School
Kameran Lashkari, MD Schepens Eye Research Institute, Harvard Medical School
Song Li, PhD University of California, Berkeley

T1D IS ON THE RISE
NEW CASES OF T1D (0-14 YEARS) PER 100,000 CHILDREN, 2013:
CONCENTRATION IN DEVELOPED MARKETS
Dabelea, Lancet, 2009

HUMAN VSELS™ ACCELERATE
HEALING IN A SCID MOUSE
COMPLEX TAIL WOUND MODEL
PRELIMINARY DATA IN A PRECLINICAL MODEL OF SEVERE COMPLEX WOUNDS SUGGEST THAT VSELS™
MAY BE MORE EFFECTIVE IN ACCELERATING HEALING THAN MESENCHYMAL STROMAL CELLS (MSCs)
FIBRIN CONTROL (DAY 7)
FIBRIN CONTROL (DAY 14)
2500 VSELs (DAY 7)
2500 VSELs (DAY 14)
A B
C D
VSELs vs. MSCs
P<0.05
% Re-epithelialization
Days Post Treatment
2,500 human VSELs
Fibrin Control
500,000 human MSCs

VSELS™ COULD BE USED TO
TREAT MACULAR DEGENERATION
Eminli, S. et al. Exploring the use of human very small embryonic-like stem cells (VSELs) isolated from adult peripheral blood for therapy of dry age-related macular degeneration
(AMD). ISSCR 2012 Annual Meeting, Yokohama, Japan. Poster presentation.
PKH-26 / RECOVERIN
PKH-26 positive cells co-labeled with Recoverin (400x).
PKH-26 / RHODOPSIN
PKH-26 positive cells co-labeled with Rhodopsin (400x).
Arrows indicate
PKH-26-labeled
cells that stain for
human recoverin
Arrows indicate
PKH-26-labeled
cells that stain for
human rhodopsin
PRELIMINARY DATA SUGGEST HUMAN VSELS™ INJECTED INTO A MOUSE SUB-RETINAL SPACE
INTEGRATE AND SHOW DIFFERENTIATION POTENTIAL IN SITU

NEOSTEM ONCOLOGY
 8 ISSUED PATENTS WITH COVERAGE INCLUDING:
 Cardiomyocytes and methods of producing and purifying cardiomyocytes
 Stem cell growth medium and methods of making and using same
 Human late stage motor neuron progenitor cells and methods of making and using
same
 Methods of derivation of neuronal progenitor cells from embryonic stem cells
 39 PATENTS PENDING WITH COVERAGE INCLUDING:
 Individualized high purity carcinoma initiating (stem) cells for target indications,
methods and use of same
 Antigen-presenting cancer vaccines
 Rapid methods to produce high purity cancer initiating (stem) cells
 Neuronal cell purification for transplantation
 Method of purification of a cell population for vascular mimicry and use of same
 Storage bags for shipment of cancer products
 Bioreactor for closed system production of cancer products

CD34 CELL PROGRAM
■ Broad and growing patent portfolio supports cardiac and other ischemic conditions
■ NeoStem’s patent claims cover a pharmaceutical composition that contains a therapeutic
concentration of non-expanded CD34/CXCR4 stem cells that move in response to SDF-1
or VEGF, together with a stabilizing amount of serum, and that can be delivered
parenterally through a catheter to repair an injury caused by vascular insufficiency
■ Six granted U.S. composition of matter and methods patents
■ 10 granted or allowed OUS composition of matter and method patents:
► European Union, Japan, South Africa, Malaysia, Philippines, Canada, Russia
■ Patent Applications: 20 U.S. and OUS patents pending
■ Issued and pending claims can be applied to broad range of other conditions caused by
underlying ischemia, including: chronic myocardial ischemia post-AMI; chronic heart
failure; critical limb ischemia; and ischemic brain injury
.

Neo stem RedChip's Global Online CEO Conference

More Related Content

What's hot (17)

Viewers also liked (18)

Similar to Neo stem RedChip's Global Online CEO Conference (20)

More from RedChip Companies, Inc. (20)

Recently uploaded (20)

Neo stem RedChip's Global Online CEO Conference